Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Authors

Stephen T Oh, Washington University School of Medicine in St. Louis
Tim Kong, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

10-10-2023

Volume

7

Issue

19

First Page

5835

Last Page

5842

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2023010151

Rights and Permissions

Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Oh, Stephen T; Kong, Tim; and et al., "Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis." Blood Advances. 7, 19. 5835 - 5842. (2023).
https://digitalcommons.wustl.edu/oa_4/3000

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.